Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population

2007 ◽  
Vol 26 (3) ◽  
pp. 453-461 ◽  
Author(s):  
H.-K. JUNG ◽  
S. HALDER ◽  
M. MCNALLY ◽  
G. R. LOCKE III ◽  
C. D. SCHLECK ◽  
...  
Keyword(s):  
Risk Factors ◽  
Irritable Bowel Syndrome ◽  
General Population ◽  
Reflux Disease ◽  
Oesophageal Reflux ◽  
Oesophageal Reflux Disease ◽  
Irritable Bowel

Irritable bowel syndrome, gastro-oesophageal reflux disease and dyspepsia: Overlap analysis using loglinear models

2012 ◽  
Vol 13 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Asma pourhoseingholi ◽  
Mohsen Vahedi ◽  
Mohamad Amin Pourhoseingholi ◽  
Sara Ashtari ◽  
Bijan Moghimi-Dehkordi ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Reflux Disease ◽  
Oesophageal Reflux ◽  
Loglinear Models ◽  
Oesophageal Reflux Disease ◽  
Overlap Analysis ◽  
Irritable Bowel

Gastro-oesophageal reflux disease and irritable bowel syndrome: a significant association in an Iranian population

2008 ◽  
Vol 20 (8) ◽  
pp. 719-725 ◽  
Author(s):  
Ali Solhpour ◽  
Mohamad Amin Pourhoseingholi ◽  
Fereshteh Soltani ◽  
Afsaneh Zarghi ◽  
Amirreza Solhpour ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Reflux Disease ◽  
Iranian Population ◽  
Oesophageal Reflux ◽  
Oesophageal Reflux Disease ◽  
Irritable Bowel

Melatonin for the treatment of gastrointestinal disorders: an overview

2021 ◽  
Vol 19 (3) ◽  
pp. 18-22
Author(s):  
David Mantle ◽  
Marcel G Smits
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Adverse Effects ◽  
Reflux Disease ◽  
Therapeutic Strategies ◽  
Oesophageal Reflux ◽  
Gastrointestinal Disorders ◽  
Pharmacological Agents ◽  
Oesophageal Reflux Disease ◽  
Irritable Bowel

Conventional pharmacological agents for the treatment of common (10–25% prevalence) gastrointestinal disorders may be associated with significant adverse effects in some patients. Therefore, there is a rationale to develop alternative therapeutic strategies for such individuals. This article reviews the evidence for the use of supplemental melatonin—a substance with an excellent safety record, free of significant adverse effects—in the management of gastro-oesophageal reflux disease, gastritis, irritable bowel syndrome and ulcerative colitis.

Sign in / Sign up

Export Citation Format

Share Document